Sunitinib is a standard first-line therapy for patients with advanced or metastatic clear-cell renal cell carcinoma. In an expanded-access study, sunitinib has demonstrated clinical benefit with an acceptable safety profile in a population of patients that is representative of those seen in clinical practice.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillance
Familial Cancer Open Access 16 November 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Motzer, R. J. et al. Sunitinib in patients with metastatic renal-cell carcinoma. JAMA 295, 2516–2524 (2006).
Motzer, R. J. et al. Sunitinib versus interferon-α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
Gore, M. E. et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 10, 757–763 (2009).
Eisen, T. et al. Sorafenib for older patients with renal-cell carcinoma: subset analysis from a randomized trial. J. Natl Cancer Inst. 100, 1454–1463 (2008).
Motzer, R. J. et al. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal-cell carcinoma. J. Clin. Oncol. 20, 289–296 (2002).
Knox, J. J. et al. The Advanced Renal-Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: safety and efficacy [abstract 5011]. J. Clin. Oncol. 25, 18S (2007).
Atkins, M. B. et al. Treatment selection for patients with metastatic renal-cell carcinoma. Cancer 115 (Suppl.), 2327–2333 (2009).
Courtney, K. D. & Choueiri, T. K. Optimizing recent advances in metastatic renal-cell carcinoma. Curr. Oncol. Rep. 11, 218–226 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T. K. Choueiri declares that he is a consultant for Bayer-Onyx, GlaxoSmithKline, Novartis and Pfizer. M. B. Atkins declares that he is a consultant for Aveo, Bayer-Onyx, Genentech, Novartis and Pfizer. M. B. Atkins is also on the speakers' bureau for Aero and has received grant/research funding from Bayer-Onyx, Genentech, Novartis and Pfizer.
Rights and permissions
About this article
Cite this article
Choueiri, T., Atkins, M. Sunitinib in RCC—expanded access equals expanded benefit?. Nat Rev Clin Oncol 6, 679–680 (2009). https://doi.org/10.1038/nrclinonc.2009.170
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.170
